website. fourth in of release, XXXX for fourth and about was issued quarter also this you very as year a of for and I Mali Zeevi, call morning, press our our of our available so we It section our quarter beyond. the and we and on Officer, are which copy today. excited with will financial Thank X-K. busy good will conference you, Relations an why of Tim everyone filed our us a results. Earlier prospects Chief thank Investor a morning, annual a is Financial results our explain discussion and begin overview Then and provide joining
BioLineRx's be we to forward. a III pre-NDA A will that in myeloma lead in successful NDA then as mid-December pre-New will Vainstein, to questions. submit looking with compelling Motixafortide in Drug or past truly cell the that sufficient growth we history other our would driver our agreement autologous and Chief pivotal for stem been which the Ella perhaps we Medical call than your transformational are Motixafortide mobilization and as any joining our patients. Also period the agency mobilization the single and call was several had Q&A has FDA forward be Application stem up months, profile more moving are to study for cell the obtain for We a our Development event The marrow Chief strengthen and company's agent Sorani, from team transplantation multiple the open for GENESIS Phase Abi Officer; Officer. our of an bone believe meeting elucidate
of primary reminder, brief The As degree administration from patients announced one transplantation high trial a one only in stem the cells after p-value apheresis stem went a optimal Motixafortide of directly III than Motixafortide very and to positive number in mobilizing significance, a May met X.XXXX. statistical of GENESIS session. cell our line of in less top XX% Approximately Phase we study results of all of only with secondary following XXXX, mobilization. endpoints and
potential a diligently were per by agency NDA XX savings that very around availability in stakeholders, proposed one midyear. from In the apheresis, higher arm has arm during versus safety the G-CSF infusion stem and to average an apheresis FDA considered where regard, number future patients in say, We higher to namely the transplantation in deliver enables cells number intend available the and million would recognize clinical the important data submission. to machines. to system. and of ability for pleased January alone. in feedback levels support G-CSF the efficiently be this that we to our agreed Needless package it’s package are addition, positively the formal that other certainty of improvements of Motixafortide meeting, a collected million often we more that our engraftment. mobilization In factors plus yet sufficient received we working kilogram to regarding submit there We of shorten finalize is only of of efficacy of adoption the the at will the care cells to will health apheresis significantly two Motixafortide and the in sessions primarily institutions units profile shortage differentiated subsequent time driven be Moreover, key be efficient believe to approved, if and an utilization by of
ran versus top of sessions. Motixafortide's In two when turn, ability combined key therefore, treatment G-CSF and to options with G-CSF of of stem driving highlighted cells autologous benefits apheresis of studies were and main G-CSF. patients Motixafortide reduce the Last mobilization the alone stem to for two alone that collection autologous care analyzed Motixafortide a HRU optimize comparing advanced process Motixafortide we G-CSF resource cell plus the Outcomes III clinical demonstrated as performed stem highlight with Our during each combination the quarter, pharmacoeconomic these and biotech the the The the in the patients, of study. Beginning plus Health to G-CSF G-CSF current G-CSF of pharma number Both with alone. plerixafor in centers we significant pharmacoeconomic research observed decrease compared combination were health with randomized was results the placebo solutions HRU, the that our during the positive of industry. multiple transplantation providers of in and studies transplantation. global and Economics and by associated utilization payers. HEOR G-CSF the mobilization GENESIS team G-CSF stem GENESIS Global study myeloma analytics, in part one to cell Research, on technology study pharmaeconomic two significant the cells in Phase leading with trial statistically of of arms, and undergoing IQVIA,
cost Given life versus number quality the $XX,XXX, cost and higher lower cells of the quality including estimates of the lifetime savings benefits number year of and care. the apheresis showed of mobilized Motixafortide of net standard adjusted not current sessions, were
benefits the lower benefits and with $XX,XXX, indirect of life on using And top These question cells option, showed cost evaluating Motixafortide to over sessions. of Based in net pharmacoeconomic and G-CSF the of number BioLineRx respect, significantly plus In results in surpassed in of cost study main a plerixafor of higher versus was previously wanted economic key other this G-CSF basis study question by well. and number treatment to also to of alone. cross-study G-CSF provides this do of reinforced benefit the methodologies BioLineRx. Motixafortide. on adjusted the IQVIA performed approximately year including Motixafortide answer savings how quality quality seen the study, not estimates mobilized We apheresis the plus combination standard comparisons how the comparing as plerixafor an on the Motixafortide lifetime
G-CSF, Motixafortide plerixafor + G-CSF. versus + For
rigorously need case of of Motixafortide GENESIS all combination treatment has trial pricing in of speaking such the in optimize substantial Further to for Together cell these unmet transplantation an that the to patients, University compelling to compelling cell case patients one showing thereafter, held cell multiple exists view for other G-CSF stem Medicine apheresis session we approved. alone believe plerixafor have savings from an pharmacoeconomic So the oral if number identified Motixafortide Motixafortide both designed presentation be alone. and the study, leave only St. were strong options standard and studies against lymphoma, top of to and GENESIS The in Annual versus of room American multiple strongly support following single should expand in the upon become the the to indications, from and Dr. expanded a a And market-leading demonstrated future cells a for as the all multiple commercial autologous with we or the our in treatment for ASH, cost Zachary pharmacoeconomic of top in Meeting Crees that undergoing of stem very nearly study XX% potential cell The care our centers. stem now in product data less provide by others. collected the and mobilization. optimal believe Hematology mobilization myeloma sickle by use patients regimen transplantation launch Louis, of G-CSF during delivered from of the ahead, Motixafortide presentation and in G-CSF new Society product for fortunate myeloma of looking of can with G-CSF. strategy we than non-Hodgkin's on the results at XX% our and the December. We the Exposition of main of myeloma Washington that the beyond G-CSF that anemia School highlight studies able administration that
four per over apheresis he still positive yields XX% trials six XX% kilogram stem fail in of patients published plerixafor and that yield sessions. noted with CDXX optimal up Specifically, of even to two cells to previously between cell million
Additionally, challenging, in of noted a advances number to for that that multiple made patients continue sufficient myeloma cells was the even it stem a trend therapies induction harvesting modern expected is in future. of the have more
and need, we have U.S., meaningful say, industry. Motixafortide delighted the clear important were need most oncology together, approved. positioned a at meetings we Needless the to for continuous the last in have At is well improved this stem new this like and fill U.S. to to a Taken are market transplants in transplantations such mobilization presence points to annually the are of therapies mobilization of if one believe point, growth over the which hematopoietic of stem over XX,XXX the an years. several overview There autologous. this cell to approximately would cell XX% shown Autologous in I opportunity provide
in U.S. the which multiple transplantation myeloma autologous agents introduction been induction cell cell stem myeloma more by in has multiple of patients. largest that the yields. cell positively of all XX% stem effective for stem in negatively put U.S. but therapies one the To impacted represents years mobilization opportunity, for impacted have exacerbated The transplants. market, three outcomes every the in recent mobilization this Within improved is this means need context, approximately
of which needed. the mobilization apheresis the either current minimum sessions transplant. mobilize of require G-CSF administrations often efficacious to for mentioned, are plus plerixafor number agents As multiple both G-CSF, treatment Thus, or options cells and are multiple more
mobilization market mobilization new based at see assessment undergoing with the use drive market myeloma of especially increased $XXX continue In indicates XXXX. value favorable a for multiple stem recent the in cell of in upfront plus be will stem use we therapy on autologous the the assessments, patients. data, plus the the transplants. through believe as million traction the stem gain which increased plerixafor cell volume cell in we to few for in dollar plerixafor the Our stem cell patients on of and our plus approximately myeloma The multiple differentiated combination estimates performance market Motixafortide potential grow Based commissioned care Associates G-CSF standard data, years cell patients. over unit coupled to ZS clinical stem we regard, product setting, of cell This G-CSF past pharmacoeconomic the autologous transplantation. continues vendor, U.S. this to stem that U.S. in third-party has especially G-CSF transplant in plerixafor mobilization,
are commercialization continue we we the if approved. to derisk and begin the through now of As asset, Motixafortide stem move need cell mindful the regulatory eventual planning in to the for process mobilization, of
stem number pharmacoeconomic stem market multiple the enables a transplant We in one of have referenced. and assessment very to cell as in collection concentrated a market XX third-party the significant just all and detailed of study the and across be with limited that agent indication. The unmet procedures. understand is United there would more the fewer centers transplant cell footprint apheresis expenses administrations XXX opportunity fewer of What for analysis we cells the that more mobilization focused Therefore, extensive launch done traditional relative is transplant broader to the required perform determined and States, a opportunity, efficacious required for oncology sessions. is roughly out myeloma, commercialization approximately have need of including XX%
opportunity dynamic encouraged this this being Given and U.S. highly with in unique the
us alone Motixafortide, taken, aggressive for the have are asset and with are we We what to route partner planning Regardless required the maintaining to from ultimately with this in prelaunch would initiated rapid under an U.S. or allows a do that to globally. launch uptake be extract the optionality launch and activities value any ensure respect and the of will either however, scenario. of most
to potentially the of approval first advancement the thrilled since are XXXX. introduce We XXXX, mobilization real in in plerixafor cell stem in
rate, previously overall pancreatic survival rate. rate response overall and IIa chemotherapy PDAC first-line as median improvement of who regard With all substantial next A combination as for our initially disease discussions final control randomized enrolled. II/III this survival, second-line study Stage to Data overall that study KEYTRUDA to COMBAT/KEYNOTE-XXX Turning unresectable X to diagnosed collaborating potential Motixafortide compared previously now of with response Phase controlled announced patients Recall cancer, median continue with therapy. program. as anti-PD-X gemcitabine-based endpoints a in or Phase including we engage in and to were of XX confirmed therapy steps study total metastatic biopharma positive following the -- from had demonstrated Motixafortide a our the program, results progression-free progressed data, with with on we've partners from indicated, goal combination we study. across PDAC Merck's a triple historical PDAC
that Regarding our that is types AGI-XXX are and evaluating mechanism September same pharmacodynamic of proof we solid quickly positive tolerability of the XXXX, we phase. both X, study array I/IIa intra-tumoral the in study. data. month, initiate later to biomarkers parameters. to anticancer second clinical assess Phase Part vaccine The safety tumor designed a moved wide And clinical safety, candidate, a dose expansion announced evaluate we in Recall and In and
to Board perspectives in in we as the experience this development. The we clinical very an completed Scientific pleased guidance Just COVID-related that formation pipeline field continue highly SAB. were enrollment immuno-oncology, a plan the the study half through December, announce is of have to of of unique Advisory announced delays To announce of and few later stage injections intra-tumoral and activities the development, brings comprised company's second that we on in way weeks we our invaluable immuno-oncology, will whom we immuno-oncology immuno-oncology and Part leaders each field the thought of of provide the the to Phase Board, I/IIa ago, along in advance some II or and regarded clinical prove now in year. despite insight readout
would fourth to pleased items. such able brief Mali, are assemble will group the in contributions. have our forward who to go call overview Zeevi, key the turn statement We look esteemed an to been give their quarter experts CFO, to like please over of I Mali our ahead. field and we now a of continued to financial
